Boehringer Ingelheim and Strados Labs to carry out pilot study of wearable biosensor technology to remotely monitor patients with idiopathic pulmonary fibrosis

Boehringer will utilize the FDA-approved Strados RESP™ Biosensor to remotely monitor cough and crackles in people with idiopathic pulmonary fibrosis to inform disease progression and the need for new treatments.

US-based Strados Labs, a health technology developer of remote respiratory devices and software, have announced they are collaborating with Boehringer Ingelheim to advance research into new treatments for idiopathic pulmonary fibrosis (IPF). In a new pilot study, Boehringer will used the FDA-cleared RESP Biosensor to monitor cough and crackles in patients with IPF at home, symptoms that have been shown to be indicative of worsening outcomes in people with IPF. Boehringer will use the data collected by the RESP Biosensor device to learn more about how these patient-reported outcomes can be used to assess the status of patients with this disease. With a history in respiratory disease research, Boehringer hopes this information will allow them to advance clinical research and drug development in IPF.

The RESP Biosensor is a lightweight, wireless lung sound measurement platform that can be worn by users to measure, record and analyze lung sounds as well as other vitals and functions remotely across healthcare settings. The device has received FDA-clearance and CE mark status and can be used by researchers and clinicians to gather insights into patients’ disease progression as well as in clinical trials with new therapies.

In the press release issued by Strados Labs, Nick Delmonico, CEO & Cofounder of the company said “Currently, disease progression in IPF is measured by a decline in forced vital capacity (FVC).” he continued. “We are thrilled to help Boehringer Ingelheim explore cough and crackles as an additional method to monitor disease while allowing patients to stay in the comfort of their homes.”